Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful
Lyell moved one of their cancer medicines to a new manufacturing center in Washington. This shows the company is getting ready to make the medicine at a bigger scale if it works in tests.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.